iShares Biotechnology ETF Newsroom

Regeneron Expands Eye Care Focus With Oxular Buyout

Seeking AlphaJan 4 02:12

Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic

BenzingaJan 4 02:08

How Is The Market Feeling About IQVIA Hldgs?

BenzingaJan 4 02:00

Viking Therapeutics Among Potential Buyout Candidates: Oppenheimer

Seeking AlphaJan 4 00:21

Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 20 Years

BenzingaJan 3 23:00

Sector Update: Health Care Stocks Lean Higher Pre-Bell Friday

MT NewswiresJan 3 22:07

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday as Investors Refocus on Economic Data

MT NewswiresJan 3 21:23

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

BenzingaJan 3 20:39

17 Analysts Assess Biogen: What You Need To Know

BenzingaJan 3 02:00

Biogen Analyst Ratings

BenzingaJan 3 00:15 · Ratings

Sector Update: Health Care Stocks Edge Higher Premarket Thursday

MT NewswiresJan 2 22:12

This Cloudflare Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

BenzingaJan 2 21:08

After experiencing a bumper harvest in 2024, the USA ETF may encounter setbacks this year.

The USA Exchange Traded Fund (ETF) received a record inflow of $1.1 trillion in 2024, but entering 2025, rapid growth may face more obstacles.

Zhitong FinanceJan 2 20:49

Analyst Expectations For Amgen's Future

BenzingaJan 2 20:00

Amgen Analyst Ratings

BenzingaJan 2 19:48 · Ratings

The competition is fierce! Musk once said that "Tirzepatide", which is more effective than semaglutide, will be launched in China. Who will dominate the weight loss drug market in 2025?

① Today, Eli Lilly and Co announced the official launch of tirzepatide in China, covering both type 2 diabetes and weight loss, and it is already available on some online platforms; ② Musk has claimed that tirzepatide is better than semaglutide, while the market is more focused on the pricing of tirzepatide and whether it will be included in medical insurance; ③ The competition in the GLP-1 sector will become even more intense in 2025, with Jiangsu Hengrui Pharmaceuticals, INNOVENT BIO, and Gan & Lee Pharmaceuticals receiving widespread attention.

cls.cnJan 2 16:20

The U.S. stock market officially closed for 2024! Among the components of the three major stock indices, who performed the best and who performed the worst?

AppLovin, a constituent stock of the Nasdaq, surged by 713%, becoming the biggest dark horse, with an increase more than four times that of AI leader NVIDIA.

wallstreetcnJan 1 17:58

Dogs Of The Dow: Top 10 High-Yield Stocks Offering Dividends Up To 6.8% In 2025

BenzingaDec 31, 2024 23:45

Sector Update: Health Care Stocks Flat to Higher Premarket Tuesday

MT NewswiresDec 31, 2024 21:58

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Tuesday Ahead of Last Trading Day of 2024

MT NewswiresDec 31, 2024 21:49